Alk Positive Nsclc clinical trials

Explore recruiting alk positive nsclc clinical trials.

Recruiting alk positive nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alk Positive Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients with Resectable Stage I-III Non-Small Cell Lung Cancer, selected according to Biomarker Status

France, Netherlands, Belgium, Denmark, Italy, Austria +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients with Completely Resected Stage Ib (Tumors ≥ 4 Cm) to Stage IIIa Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer

Romania, Denmark, Spain, Austria, Hungary, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)

Belgium, Netherlands, France, Spain, Germany, Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Italy, Austria, France, Denmark, Greece, Hungary +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

eXALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Poland, France, Spain, Czechia, Belgium, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

B7461006 - A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER

Poland, Netherlands, Belgium, Czechia, Italy, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Alk Positive Nsclc trials by city

Alk Positive Nsclc in Toronto Alk Positive Nsclc in Vancouver Alk Positive Nsclc in Montreal Alk Positive Nsclc in Calgary Alk Positive Nsclc in Edmonton Alk Positive Nsclc in Ottawa Alk Positive Nsclc in Winnipeg Alk Positive Nsclc in Quebec City Alk Positive Nsclc in Hamilton Alk Positive Nsclc in Kitchener Alk Positive Nsclc in London Alk Positive Nsclc in Halifax Alk Positive Nsclc in New York Alk Positive Nsclc in Los Angeles Alk Positive Nsclc in Chicago Alk Positive Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease